Call Buying Activity in AbbVie (ABBV) Targets 3% Upside in Shares Into Mid-November Ahead Various Drug Trials -Susquehanna

Susquehanna option strategist Alison Edwards notes call buying in AbbVie (NYSE: ABBV) ahead of various drug trials, as investors purchased Nov 91 Calls with roughly 7,500 trading for $1.25, targeting 3% upside into mid-Nov.

You May Also Be Interested In

• Abbvie (ABBV) PT Raised to $273 at Canaccord
• FedEx (FDX) call put ratio 1 call to 1.8 puts into quarter results
• Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patie